Abstract
To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon-like peptide-1 receptor agonist, liraglutide (IDegLira), was consistently effective in patients with type 2 diabetes (T2D), regardless of the stage of T2D progression. Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks) randomized trials, the efficacy of IDegLira was investigated with regard to measures of disease progression stage including baseline glycated haemoglobin (HbA1c), disease duration and previous insulin dose. Across four categories of baseline HbA1c (≤7.5-9.0%), HbA1c reductions were significantly greater with IDegLira (1.1-2.5%) compared with IDeg or liraglutide alone in DUAL I. In DUAL II, HbA1c reductions were significantly greater with IDegLira (0.9-2.5%) than with IDeg in all but the lowest HbA1c category. In DUAL I, insulin dose and hypoglycaemia rate were lower across all baseline HbA1c categories for IDegLira versus IDeg, while hypoglycaemia was higher with IDegLira than liraglutide, irrespective of baseline HbA1c. In DUAL II, insu...Continue Reading
References
Jul 1, 1999·Quality Assurance : QA·J R Dixon
Mar 1, 2005·British Journal of Anaesthesia·R RaobaikadyR M Grounds
Oct 27, 2005·Diabetes Care·Mark PeyrotUNKNOWN International DAWN Advisory Panel
Apr 16, 2010·Primary Care Diabetes·Jeremy DaleRoger Gadsby
Jan 17, 2012·Diabetes Research and Clinical Practice·Bruce Bode
Feb 9, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·M PeyrotP-M Schumm-Draeger
Mar 27, 2012·Diabetes, Obesity & Metabolism·K KhuntiUNKNOWN SOLVE Study Group
Sep 4, 2012·Current Medical Research and Opinion·Ning WuKelly Wilkey
Apr 27, 2013·Drugs·Gillian M Keating
Jul 24, 2013·Diabetes Care·Kamlesh KhuntiMelanie J Davies
Aug 2, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jiten VoraSteve C Bain
Aug 13, 2014·Diabetes Care·John B BuseUNKNOWN NN9068-3912 (DUAL-II) Trial Investigators
Sep 6, 2014·The Lancet. Diabetes & Endocrinology·Stephen C L GoughUNKNOWN NN9068-3697 (DUAL-I) trial investigators
May 20, 2015·Diabetes, Obesity & Metabolism·S C L GoughJ B Buse
Citations
Jun 24, 2016·Expert Review of Endocrinology & Metabolism·Stephen Cl GoughVincent C Woo
Feb 20, 2016·Clinical Drug Investigation·Tina VilsbøllLawrence Blonde
Aug 4, 2016·Expert Opinion on Biological Therapy·K StinkensC Mathieu
Jul 29, 2016·Expert Opinion on Drug Metabolism & Toxicology·Elizabeth Mary Lamos, Stephen N Davis
Feb 6, 2017·Advanced Drug Delivery Reviews·Sergei PechenovJ Anand Subramony
Mar 30, 2017·Expert Review of Clinical Pharmacology·Lauge ØstergaardSten Madsbad
Apr 23, 2017·Diabetes, Obesity & Metabolism·Melanie J DaviesJulio Rosenstock
Apr 19, 2017·Diabetes, Obesity & Metabolism·Paul NorwoodSimon Heller
Aug 12, 2017·The Annals of Pharmacotherapy·Kira Harris, Kimberly Lovin Nealy
Aug 15, 2017·Hospital Pharmacy·Danial E Baker
Jun 24, 2017·Diabetes, Obesity & Metabolism·Ildiko LingvayEsteban Jódar
Jun 6, 2018·Diabetes Technology & Therapeutics·Helena W Rodbard
Apr 11, 2018·Diabetology & Metabolic Syndrome·Rodrigo Oliveira MoreiraRaquel C Lopes Assis Coelho
Feb 22, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Daniela Sofra
Mar 14, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lawrence BlondeDenis Raccah
Jan 6, 2019·Advances in Therapy·Leigh PerreaultEric Johnson
Feb 18, 2021·Journal of Diabetes Investigation·Mitsuhisa KomatsuKohei Kaku
Oct 14, 2021·Expert Opinion on Drug Safety·Peter Novodvorský, Martin Haluzík
Oct 23, 2021·Diabetes, Obesity & Metabolism·Kevin CowartNicholas W Carris